BC Week In Review | Nov 9, 2018
Company News

Cue, LG in biologics deal

Cue Biopharma Inc. (NASDAQ:CUE) granted LG Chem Life Sciences exclusive development and commercialization rights in certain Asian-Pacific countries, including Japan, China and Korea, and Australia to CUE-101 and Cue's Immuno-STAT biologics that target T cells...
BC Week In Review | Sep 29, 2017
Financial News

Cue Biopharma proposes $40M IPO

On Sept. 21, cancer play Cue Biopharma Inc. (Cambridge, Mass.) proposed to raise up to $40 million in an IPO on NASDAQ underwritten by MDB Capital Group and Feltl. Cue emerged from stealth mode in...
BC Extra | Sep 22, 2017
Financial News

Cue Biopharma proposes $40M IPO

Cancer play Cue Biopharma Inc. (Cambridge, Mass.) proposed to raise up to $40 million in an IPO on NASDAQ underwritten by MDB Capital Group and Feltl. Cue emerged from stealth mode in January with a...
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

Recombinant IL-2 was one of the first immunotherapies marketed for cancer but is not widely used due to severe off-target toxicities. Cue Biopharma Inc. is developing preclinical programs that deliver IL-2 only to T cells...
BioCentury | Jan 27, 2017
Finance

Activation on cue

Cue Biopharma Inc. emerged from stealth mode last week with a financing led by MDB Capital Group that will enable the cancer play to reach the clinic with its lead therapy, which could trigger a...
BC Extra | Jan 25, 2017
Financial News

Cue Biopharma launches, reveals funding

Cancer immunotherapy company Cue Biopharma Inc. (Cambridge, Mass.) launched Tuesday and announced the close of a $16.4 million round led by MDB Capital Group. The company is developing modular biologics that join a T cell...
Items per page:
1 - 6 of 6